Shares of Benitec Biopharma Limited BNTC) have shown positive gains in today’s trading session. At the time of writing, the stock had hit $1.62. This represents a change from the opening price of 9.36%. The year-to-date performance of the stock is -63.18%. The monthly stock performance comes in at -13.45%. For the quarter, shares are performing at -58.77%. Weekly performance analysis shows the equity at -12.94%.
Certain covering analysts have provided recommendations and price target projections on Benitec Biopharma Limited BNTC). First Call currently has the consensus target price on the stock at $14.00. Analysts have also given a consensus recommendation on the stock of 2.00. This value is based on a numerical scale of 1 to 5. Analysts giving the rating a 4 or 5 are indicating a Sell. Analysts giving the company a 1 or 2 are indicating a Buy. A 3 rating would indicate a Hold on the equity.
Benitec Biopharma Limited shares are currently 32.66% away from the 52 week low. Alternately, the stock is separated -88.57% from the 52 week high. The stock is 32.66% away from its 50 day low and -55.90% away from the 50 day high. Relative to the 20 day Simple Moving Average, shares are trading -1.56% away. Shares are currently separated from the 50 day Simple Moving Average by -13.94%. Shares are currently separated from the 200 day Simple Moving Average by -70.03%. The company’s Relative Strength Index (RSI) currently stands at 48.38.
BLT Price at posting:
11.5¢ Sentiment: None Disclosure: Held
BNTC) have shown positive gains in today’s trading session. At the time of writing, the stock had hit $1.62. This represents a change from the opening price of 9.36%. The year-to-date performance of the stock is -63.18%. The monthly stock performance comes in at -13.45%. For the quarter, shares are performing at -58.77%. Weekly performance analysis shows the equity at -12.94%.
